Essen, Germany. Evonik will continue to optimize its global methionine production setup for MetAMINO® (DL-methionine) in the third and fourth quarter of 2025. Implementation of several technical measures requires a shutdown of the production facilities for methionine and its precursors for 6-7 weeks each at Evonik's Singapore site in August/September and at its Antwerp site in September/October 2025.
In Singapore, the maintenance schedule of a raw material supplier necessitates an early shutdown in Q3. Evonik will synchronize this with the catalyst exchange in its methionine production and take this opportunity to further improve the energy efficiency and CO2 emissions of the plant.
In Antwerp, Evonik will also combine a catalyst exchange with the continuation of the measures begun in May to reduce nitrogen, sulphur, and CO2 emissions. During the shutdown of the methionine facilities for 6-7 weeks in September and October, Evonik Antwerp site operations will implement further milestones from its climate roadmap and make the site’s utilities infrastructure fit for the future. These upgrades are major enablers contributing to further reductions in the carbon footprint of Evonik’s production facilities.
“With our global production setup for MetAMINO® we continue to ensure supply security for our customers worldwide for the years to come. MetAMINO® also has a product carbon footprint that is approximately 35 percent lower than the calculated global industry average*. This is the result of our constant efforts tooptimize our assets”, said Dr. Dirk Hoehler, head of the amino acids business of Evonik’s Animal Nutrition business line.
MetAMINO® is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line of Evonik develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein.
*Methodology for global industry average excluding Evonik: estimated internally by Evonik‘s market intelligence, technology and lifecycle assessment experts. Industry methionine sources include DL-methionine, L-methionine and methionine hydroxy analogue (MHA). Global Warming Potential is estimated accounting for the higher bioavailability of methionine in MetAMINO® versus MHA.
